ABSTRACT We describe the opioid properties of a tridecapeptide, the sequence of which corresponds to the NH2-terminal sequence of dynorphin, a novel porcine pituitary endorphin. It The first pituitary opioid peptide to be discovered (1, 2) had properties quite different from those of /3-endorphin. It had a lower apparent molecular weight, was more basic, and had a more persistent effect in the guinea pig ileum bioassay. Also, its biologic activity (unlike that of f3-endorphin) was resistant to destruction by cyanogen bromide. The final stages of purification presented special problems, which led to erroneous conclusions about composition and the presence of a blocked NH2 terminus (3). Losses due to adsorption were particularly troublesome, and the material proved to be remarkably potent; consequently, the yield of purified product was much less than anticipated. However, by means of microsequencing technology (4, 5), we have now been able to determine the sequence of the first 13 residues.
The first pituitary opioid peptide to be discovered (1, 2) had properties quite different from those of /3-endorphin. It had a lower apparent molecular weight, was more basic, and had a more persistent effect in the guinea pig ileum bioassay. Also, its biologic activity (unlike that of f3-endorphin) was resistant to destruction by cyanogen bromide. The final stages of purification presented special problems, which led to erroneous conclusions about composition and the presence of a blocked NH2 terminus (3) . Losses due to adsorption were particularly troublesome, and the material proved to be remarkably potent; consequently, the yield of purified product was much less than anticipated. However, by means of microsequencing technology (4, 5), we have now been able to determine the sequence of the first 13 residues.
To denote its extraordinary potency, the natural peptide has been named "dynorphin" (dyn-from Greek dynamis = power). Synthetic dynorphin-(1-13) proved to have approximately the same high potency as natural dynorphin. We describe here some properties of this synthetic tridecapeptide.
MATERIALS AND METHODS
Purification and Partial Sequence Determination of Porcine Dynorphin. Starting material was 100 g of melanotropin concentrate, the second oxycellulose adsorbate in commercial corticotropin production from porcine pituitary glands (6) . The initial steps, with 25-g batches, have been described (2) : extraction and back-extraction with butanol; separation from ,B-endorphin on Bio-Gel P-6; preparative reversed-phase high-performance liquid chromatography on C18 columns, first with a methanol gradient in trifluoroacetic acid and then with an acetonitrile gradient in Tris buffer at neutrality, followed by elution of the active material with trifluoroacetic acid. Every step was monitored by assay on the guinea pig ileum myenteric plexus longitudinal muscle preparation (7, 8) .
Pooled material from four batches, obtained as above, was loaded on a Bio-Gel column (P-6/P-4, 4:1; 1.5 X 90 cm) in 0.1 M (NH4)2CO0 at pH 8.7. Fractions (1.7 ml, 15 min) were tested for activity in the bioassay. The peak of slow-reversing activity (2) (fractions 65-75) was lyophilized and then further purified on CM-Sephadex (0.9 X 30 cm) equilibrated with 12.5 mM sodium borate at pH 11.0. The material was eluted with a 160-ml linear gradient from the starting buffer to 0.1 M phosphate buffer at pH 12.0. Fractions (2.0 ml; 15 min) were collected and assayed. Slow-reversing activity emerged between 94 and 106 ml. The two peak tubes, containing 50% of the activity, were pooled and desalted on Bio-Gel P-2 (1.5 X 90 cm) in n-butanol/acetic acid/water, 2:1:4 (vol/vol).
Finally, the desalted material was subjected to reverse-phase chromatography (high-performance liquid chromatography, C18 column) using a 10-50% acetonitrile gradient in 5 mM trifluoroacetic acid. The peak of biologic activity had no measurable absorbance at 280 nm. A rough estimate of quantity from absorbance at 225 and 215 nm indicated the presence of only a few micrograms of peptide, but the activity in the bioassay was equivalent to 334 nmol of normorphine (range, 189-525 in four tissue strips).
One-third of the material was dansylated (DNS), applied to a silica gel 60 H (Merck) thin-layer chromatography plate, and developed in methyl acetate/isopropanol/ammonia, 9:7:4 (vol/vol). Two fluorescent bands were observed with RF = 0 (band 1) and Rf = 0.20 (band 2). Each band was extracted with methanol/pyridine/acetic acid, 1:1:1 (vol/vol), and demonstrated to be homogeneous by thin-layer chromatography in n-butanol/acetic acid/water, 4 With one-third of the total material, an unambiguous sequence was obtained for 13 residues (Fig. 1) . Two related peptides (referred to here as "register-shift peptides") were also synthesized by Peninsula Laboratories. These were the des-Arg6 dodecapeptide from dynorphin-(1-13) and the Gly6 tetradecapeptide derivative in which glycine is inserted between Leu5 and Arg6. Standards of purity were the same as noted above for the tridecapeptide.
Biologic Activity. Dilutions for all bioassays were made in methanol/0.1 M HC1, 1:1 (vol/vol); dilutions for radioimmunoassays were in 50 mM phosphate, pH 7.4/50 mM NaCI/0.1% bovine serum albumin/0.5% Triton X-100. Use of these solvents was dictated by our experience with losses to glass, plastic, and other surfaces during purification of the natural dynorphin and by experiments using 125I-labeled dynorphin-(1-13).
The guinea pig ileum myenteric plexus longitudinal muscle preparation was used as described (7, 8 5 10
Tyr-GI y-Gly-Phe-Leu-Arg-Arg-lle-Arg-Pro-Lys-Leu-Lys- (14, 15) . Antisera were used at final dilutions required to bind about 30% of 125I-labeled [Leu] enkephalin in the absence of a competing ligand. This radioligand was prepared by the chloramine-T method (13) and purified on DEAE-Sephadex. In each tube, 100,ul of peptide to be assayed was added to 100lu of diluted antiserum, and the mixture was incubated for 48 hr at 4°C. Then, 100 Al of radioligand (;5000 cpm) was added, and incubation was continued for another 24 hr. The incubation was terminated by adding 100lu of normal rabbit plasma and 1.5 ml of 15.8% polyethylene glycol. After 10 min on ice, the mixture was centrifuged for 15 min at 4000 X g, the supernatant solution was aspirated, and the tube containing precipitate was placed in a gamma counter. RESULTS Typical opioid effects of dynorphin-(1-13) in the two bioassays are shown in Fig. 2 approximately equipotent in the two tissues, and dynorphin-(1-13) was 12 times more potent in the guinea pig ileum preparation.
The potencies of the two register-shift peptides in the guinea pig ileum preparation are summarized at bottom of Table 1 .
These peptides are identical to dynorphin-(1-13) except that in RS-1 a deletion of Arg6 shifts the remaining COOH-terminal sequence to the left by about 0.5 nm and in RS-2 an insertion of Gly6 shifts the remaining sequence to the right by the same amount. The loss of potency in both, compared with the parent peptide, makes it evident that the unique sequence embodied in dynorphin- (6) (7) (8) (9) (10) (11) (12) (13) , and the linear distance of this sequence from the [Leulenkephalin sequence [dynorphin-(1-5)], are both critically important for maximal potency.
We studied the rate of reversal of twitch inhibition upon washing the guinea pig ileum preparation. First, a moderate degree of inhibition was established (range, 41-72%). Then, the bath fluid was replaced and twitch amplitude was measured again 3 min later. With this procedure, 21% and 22% recovery had been noted in two preparations of purified natural dynorphin. Mean (+SEM) recoveries for other agonists, with number of experiments in parentheses, were: synthetic dynorphin-(1-13), 13 + 2% (7); fc-endorphin, 45 + 5% (4); normorphine, 78 ± 4% (7); [Leu]enkephalin, 101 + 1% (4). Thus, the synthetic peptide was slow-reversing. Rate of reversal, which is influenced by the ligand-receptor dissociation rate constant, tends to be slower with more potent ligands. Table 2 gives the results in the radioreceptor binding assay with washed rat brain membranes. Dynorphin-(1-13) was less potent than fc-endorphin, approximately equipotent with normorphine, and much more potent than [Leu]enkephalin. With [3H]naloxone as radioligand, the decreased affinity of dynorphin-(1-13) in the presence of 100 mM NaCl was typical of the "sodium shift" seen with agonists when an antagonist is radioligand. In some of the incubations, with the new peptide at approximately its IC5o concentration, 125I-labeled dynorphin-(1-13) was added. At the end of the incubation, analysis of radioactivity on a molecular sieving gel column revealed that all of the original peptide had been degraded to material of lower apparent molecular weight. Thus, the observed potencies of the new peptide in this assay must be regarded as [Leu]enkephalin, this rarely occurred. Naloxone is l/3th as potent in blocking this peptide as it is in blocking normorphine or [Leu] enkephalin, but complete blockade is nevertheless obtained at high enough concentrations. In additivity experiments, the peptide had no antagonist properties in this tissue.
In the mouse vas deferens, in which degradation is also not seen, the peptide is about 3 times more potent than [Leu] IC50 values were obtained from assays spanning the 50%o inhibition response, plotted as in Fig. 1 . Naloxone Kd is the apparent dissociation constant of the antagonist, computed from the equation Kd = C/(DR -1), derived from the mass raw for competitive antagonism, in which C is concentration of naloxone (here, 100 nM), and DR is dose ratio of agonist [the ratio of IC50 doses in the presence and absence of the antagonist (9) ]. The same procedures were followed with the mouse vas deferens. IC50 values are geometric means; SEM are in log units; number of tissue preparations is shown in parentheses. Kd determinations were based on four tissue preparations. RS-1 is des-Arg6-dynorphin-(1-13); RS-2 has Gly6 inserted in dynorphin-(1-13).
in that its potency is relatively much greater in the guinea pig ileum than in the mouse vas. Dynorphin-(1-13) competes with opiate alkaloid and opioid peptide radioligands for stereospecific binding to rat brain membranes. It is not exceptionally potent in this assay, but that may be due to its demonstrated rapid degradation by a membrane-bound enzyme. Its sodium shift is typical of that seen with agonists such as normorphine and fC-endorphin.
Artificial enhancement of the potency of enkephalins has been achieved primarily through synthesis of analogues (such as the D-Ala2 derivatives) less subject to attack by degradative enzymes (17) . The greater potency of f3-endorphin than of [Met] enkephalin [f3-endorphin-(1-5)] is also associated with greater metabolic stability (18) . A different basis for high potency is evident in the structure of dynorphin-(1-13). The sequence -Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-OH, as a COOHterminal extension of [Leujenkephalin, enhances the potency of that pentapeptide by nearly 3 orders of magnitude in the. guinea pig ileum preparation and also results in a greatly decreased apparent affinity of naloxone as an antagonist. If this tissue contains more than one type of opiate receptor (16, 19, 20) , it follows that the [Leu]enkephalin receptor is different from the dynorphin receptor with respect to affinity both for these peptide ligands and for naloxone.
The dynorphin receptor evidently has an extensive binding site, of which only one part interacts with enkephalin penta- 
